Drug Profile
Research programme: bispecific NK cell engagers - Innate Pharma/Sanofi
Alternative Names: Bispecific NK cell engaging antibodies - Innate Pharma/Sanofi; NK-cell engagers; NK-cell engagers - Innate Pharma; NKCEs; NKCEs - Innate Pharma; NKp46 NKCEs; SAN-NKCE-1Latest Information Update: 06 Jun 2023
Price :
$50
*
At a glance
- Originator Innate Pharma
- Developer Innate Pharma; Sanofi
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer